Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share for the year ending December 31, 2023: USD 0.03

Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share is USD 0.03 for the year ending December 31, 2023, a 6,504.35% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
  • Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share for the year ending December 31, 2022 was USD 0.00, a -23.16% change year over year.
  • Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
  • Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share for the year ending December 31, 2020 was USD -0.00, a 0.00% change year over year.
  • Shanghai Yizhong Pharmaceutical Co., Ltd. Dividend Per Share for the year ending December 31, 2019 was USD -0.00, a 0.00% change year over year.
Key data
Date Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE)
Market news
Loading...
Shanghai Stock Exchange: 688091.SS

Shanghai Yizhong Pharmaceutical Co., Ltd.

CEO Mr. Jingsong Zhou
IPO Date Sept. 9, 2021
Location China
Headquarters No.79 Renqi Road
Employees 304
Sector Health Care
Industries
Description

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. The company was founded in 2009 and is based in Shanghai, China.

Similar companies

002004.SZ

Huapont Life Sciences Co., Ltd.

USD 0.59

1.41%

600518.SS

Kangmei Pharmaceutical Co., Ltd.

USD 0.31

4.14%

600079.SS

Humanwell Healthcare (Group) Co.,Ltd.

USD 2.91

1.87%

002332.SZ

Zhejiang Xianju Pharmaceutical Co.,Ltd.

USD 1.34

1.98%

002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

USD 2.60

1.18%

StockViz Staff

January 16, 2025

Any question? Send us an email